enGene Rebrands as enGene Therapeutics Ahead of Potential 2027 Commercial Launch
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
enGene Holdings ( (ENGN) ) has issued an announcement.
enGene Therapeutics Inc. has changed its corporate name from enGene Holdings Inc., signaling its transition from a development-stage biotech to a potential commercial organization as it advances detalimogene voraplasmid toward a possible 2027 approval. The company is continuing its LEGEND trial in high-risk non-muscle invasive bladder cancer, while its shares and warrants will maintain their Nasdaq tickers but receive new CUSIP and ISIN identifiers, leaving existing security holder rights unaffected.
detalimogene voraplasmid targets patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, an area of high unmet medical need often leading to cystectomy, and has secured RMAT and Fast Track designations as well as inclusion in the FDA’s CMC Development and Readiness Pilot program. These regulatory advantages and the ongoing pivotal cohort in BCG-unresponsive carcinoma in situ position enGene to potentially accelerate development and commercialization timelines, bolstering its standing in the gene therapy and bladder cancer treatment landscape.
The most recent analyst rating on (ENGN) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on enGene Holdings stock, see the ENGN Stock Forecast page.
Spark’s Take on ENGN Stock
According to Spark, TipRanks’ AI Analyst, ENGN is a Neutral.
The score is held down primarily by weak financial performance (no revenue, inconsistent profitability, and substantial ongoing cash burn) and bearish technicals (price below key moving averages with negative MACD and very low RSI/stochastics). A low P/E and a relatively strong balance sheet provide partial support but do not offset the operating and cash-flow risks.
To see Spark’s full report on ENGN stock, click here.
More about enGene Holdings
enGene Therapeutics Inc. is a clinical-stage, non-viral genetic medicines company focused on developing gene therapies for high-risk non-muscle invasive bladder cancer. Its lead investigational therapy, detalimogene voraplasmid, is delivered directly into the bladder and built on the company’s Dually Derivatized Oligochitosan platform, which aims to simplify manufacturing, handling and administration versus viral-based gene therapies.
Average Trading Volume: 429,794
Technical Sentiment Signal: Sell
Current Market Cap: $485M
For detailed information about ENGN stock, go to TipRanks’ Stock Analysis page.
